Antidiabetic effects of sub-chronic administration of the cannabinoid receptor (CB1) antagonist, AM251, in obese diabetic (ob/ob) mice

Nigel Irwin, Kerry Hunter, Nonna Frizzell, Peter Flatt

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Recent research suggests that cannabinoid CB1 receptor antagonism reduces appetite and body weight gain. The present study was designed to assess the sub-chronic effects of the selective cannabinoid CB1 receptor antagonist, AM251 (N-(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4dichlorophenyl)-4-methyl-1H-p yrazole-3-carboxamide), in young ob/ob mice. Pair-fed animals were used as additional controls. Daily injection of AM251 (6 mg/kg body weight) for 18 days significantly (P <0.05) decreased daily and 18-day cumulative food intake. The corresponding body weight change did not achieve significance and values were not different from pair-fed mice. Non-fasting plasma glucose was decreased (P <0.05) from day 10 onwards by AM251 treatment. The glycaemic response to intraperitoneal glucose was correspondingly improved (P <0.05) in AM251 treated mice. In keeping with this, insulin sensitivity was enhanced (P <0.05) compared to controls. Furthermore, adipose mRNA levels of acetyl-CoA carboxylase I were significantly (P <0.05) reduced by 18 days AM251 treatment. There were no differences in either non-fasting or glucose-stimulated insulin release. Pair-feeding had broadly similar metabolic effects to AM251 treatment apart from increased (P <0.01) locomotor activity which was only observed in AM251 treated ob/ob mice. These data indicate that sub-chronic antagonism of the cannabinoid CB1 receptor by daily treatment with AM251 counters aspects of the hyperphagia-related impairment of ob/ob mouse metabolism. Such effects seem predominantly mediated by restriction of energy intake. (c) 2008 Elsevier B.V All rights reserved.
LanguageEnglish
Pages226-233
JournalEuropean Journal of Pharmacology
Volume581
Issue number1-2
DOIs
Publication statusPublished - Feb 2008

Fingerprint

Cannabinoid Receptor Antagonists
Cannabinoid Receptor CB1
Hypoglycemic Agents
Glucose
Body Weight
Acetyl-CoA Carboxylase
Hyperphagia
Body Weight Changes
AM 251
Appetite
Therapeutics
Locomotion
Energy Intake
Weight Gain
Insulin Resistance
Eating
Insulin
Messenger RNA
Injections

Cite this

@article{9218e4b5ce884254b2bcfed3e42c1c02,
title = "Antidiabetic effects of sub-chronic administration of the cannabinoid receptor (CB1) antagonist, AM251, in obese diabetic (ob/ob) mice",
abstract = "Recent research suggests that cannabinoid CB1 receptor antagonism reduces appetite and body weight gain. The present study was designed to assess the sub-chronic effects of the selective cannabinoid CB1 receptor antagonist, AM251 (N-(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4dichlorophenyl)-4-methyl-1H-p yrazole-3-carboxamide), in young ob/ob mice. Pair-fed animals were used as additional controls. Daily injection of AM251 (6 mg/kg body weight) for 18 days significantly (P <0.05) decreased daily and 18-day cumulative food intake. The corresponding body weight change did not achieve significance and values were not different from pair-fed mice. Non-fasting plasma glucose was decreased (P <0.05) from day 10 onwards by AM251 treatment. The glycaemic response to intraperitoneal glucose was correspondingly improved (P <0.05) in AM251 treated mice. In keeping with this, insulin sensitivity was enhanced (P <0.05) compared to controls. Furthermore, adipose mRNA levels of acetyl-CoA carboxylase I were significantly (P <0.05) reduced by 18 days AM251 treatment. There were no differences in either non-fasting or glucose-stimulated insulin release. Pair-feeding had broadly similar metabolic effects to AM251 treatment apart from increased (P <0.01) locomotor activity which was only observed in AM251 treated ob/ob mice. These data indicate that sub-chronic antagonism of the cannabinoid CB1 receptor by daily treatment with AM251 counters aspects of the hyperphagia-related impairment of ob/ob mouse metabolism. Such effects seem predominantly mediated by restriction of energy intake. (c) 2008 Elsevier B.V All rights reserved.",
author = "Nigel Irwin and Kerry Hunter and Nonna Frizzell and Peter Flatt",
year = "2008",
month = "2",
doi = "10.1016/j.ejphar.2007.12.003",
language = "English",
volume = "581",
pages = "226--233",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-2",

}

Antidiabetic effects of sub-chronic administration of the cannabinoid receptor (CB1) antagonist, AM251, in obese diabetic (ob/ob) mice. / Irwin, Nigel; Hunter, Kerry; Frizzell, Nonna; Flatt, Peter.

In: European Journal of Pharmacology, Vol. 581, No. 1-2, 02.2008, p. 226-233.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Antidiabetic effects of sub-chronic administration of the cannabinoid receptor (CB1) antagonist, AM251, in obese diabetic (ob/ob) mice

AU - Irwin, Nigel

AU - Hunter, Kerry

AU - Frizzell, Nonna

AU - Flatt, Peter

PY - 2008/2

Y1 - 2008/2

N2 - Recent research suggests that cannabinoid CB1 receptor antagonism reduces appetite and body weight gain. The present study was designed to assess the sub-chronic effects of the selective cannabinoid CB1 receptor antagonist, AM251 (N-(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4dichlorophenyl)-4-methyl-1H-p yrazole-3-carboxamide), in young ob/ob mice. Pair-fed animals were used as additional controls. Daily injection of AM251 (6 mg/kg body weight) for 18 days significantly (P <0.05) decreased daily and 18-day cumulative food intake. The corresponding body weight change did not achieve significance and values were not different from pair-fed mice. Non-fasting plasma glucose was decreased (P <0.05) from day 10 onwards by AM251 treatment. The glycaemic response to intraperitoneal glucose was correspondingly improved (P <0.05) in AM251 treated mice. In keeping with this, insulin sensitivity was enhanced (P <0.05) compared to controls. Furthermore, adipose mRNA levels of acetyl-CoA carboxylase I were significantly (P <0.05) reduced by 18 days AM251 treatment. There were no differences in either non-fasting or glucose-stimulated insulin release. Pair-feeding had broadly similar metabolic effects to AM251 treatment apart from increased (P <0.01) locomotor activity which was only observed in AM251 treated ob/ob mice. These data indicate that sub-chronic antagonism of the cannabinoid CB1 receptor by daily treatment with AM251 counters aspects of the hyperphagia-related impairment of ob/ob mouse metabolism. Such effects seem predominantly mediated by restriction of energy intake. (c) 2008 Elsevier B.V All rights reserved.

AB - Recent research suggests that cannabinoid CB1 receptor antagonism reduces appetite and body weight gain. The present study was designed to assess the sub-chronic effects of the selective cannabinoid CB1 receptor antagonist, AM251 (N-(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4dichlorophenyl)-4-methyl-1H-p yrazole-3-carboxamide), in young ob/ob mice. Pair-fed animals were used as additional controls. Daily injection of AM251 (6 mg/kg body weight) for 18 days significantly (P <0.05) decreased daily and 18-day cumulative food intake. The corresponding body weight change did not achieve significance and values were not different from pair-fed mice. Non-fasting plasma glucose was decreased (P <0.05) from day 10 onwards by AM251 treatment. The glycaemic response to intraperitoneal glucose was correspondingly improved (P <0.05) in AM251 treated mice. In keeping with this, insulin sensitivity was enhanced (P <0.05) compared to controls. Furthermore, adipose mRNA levels of acetyl-CoA carboxylase I were significantly (P <0.05) reduced by 18 days AM251 treatment. There were no differences in either non-fasting or glucose-stimulated insulin release. Pair-feeding had broadly similar metabolic effects to AM251 treatment apart from increased (P <0.01) locomotor activity which was only observed in AM251 treated ob/ob mice. These data indicate that sub-chronic antagonism of the cannabinoid CB1 receptor by daily treatment with AM251 counters aspects of the hyperphagia-related impairment of ob/ob mouse metabolism. Such effects seem predominantly mediated by restriction of energy intake. (c) 2008 Elsevier B.V All rights reserved.

U2 - 10.1016/j.ejphar.2007.12.003

DO - 10.1016/j.ejphar.2007.12.003

M3 - Article

VL - 581

SP - 226

EP - 233

JO - European Journal of Pharmacology

T2 - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-2

ER -